The goals of our Center, "Modifiers of FRM1-associated disorders: application of high throughput technologies', are targeted to the RFA research area to Advance the understanding of the pathophysiology of FMR1 Related Conditions. The completion of the proposed aims from the three research projects will lead to the identification of the genetic basis of variable expressivity or incomplete penetrance of FRM1-associated conditions. Project A will focus on the variable expression of epilepsy among boys with fragile X syndrome (FXS), a co-morbid condition that occurs among 15% of affected boys and we speculate that variation elsewhere in the genome is responsible. Likewise, Project B will focus on the incomplete penetrance of fragile X tremor/ataxia syndrome (FXTAS) in men, a neurodegenerative disorder among those with the premutation (PM), with a lifetime prevalence of 30% among males. Project C focuses fragile X association primary ovarian insufficiency (FXPOl) which manifests in 20% of PM carriers as premature ovarian failure (POF), or cessation of menses prior to age 40. POF leads to infertility and estrogen-deficiency related disorders usually reserved for the aged. Our goal is to identify and understand the extent of the epistatic effects of modifying genes on these three Mendelian disorders. The Center will include three projects and two shared cores, all administered by an Administrative Core. Each proposed research project will take the same novel approach to define a set of candidate genes for further study in mammalian systems. They will: 1) use the Recruitment Core B to ascertain the 100 cases and 100 controls drawn from extreme phenotypic tails of each disorder, 2) conduct whole genome sequencing on each of the 100/100 cases/controls series using the expertise and experience of the Genomics and Analytical Core C, and 3) after validating variants, assess the function of prioritized genes using the established phenotypic assays in the corresponding Drosophila models.
The aims of the Administrative Core are to: 1) provide leadership and a center structure within which investigators can integrate their ideas, expertise and results, 2) facilitate communication and reporting of results to the scientific community, 3) facilitate research tasks by providing guidance in regulatory processes, budgeting, ordering and preparation of manuscripts and presentations, 4) facilitate data and resource sharing, and 5) provide coordinated research opportunities for students and postdoctoral fellows to engage them in fragile X-related conditions.
The identification of genes whose variation modifies the phenotype of a Mendelian disorder is emerging at the forefront of contemporary human genetics. Characterizing those modifying genes for fragile X syndrome-associated epilepsy, fragile X-associated ovarian insufficiency and fragile X-associated tremor/ataxia syndrome will increase the understanding of perturbed pathways involved in these disorders.